Eli Lilly and Company $LLY Stake Boosted by Generate Investment Management Ltd

Generate Investment Management Ltd boosted its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 8.4% during the third quarter, Holdings Channel.com reports. The institutional investor owned 57,065 shares of the company’s stock after acquiring an additional 4,409 shares during the quarter. Eli Lilly and Company accounts for approximately 2.6% of Generate Investment Management Ltd’s portfolio, making the stock its 11th largest position. Generate Investment Management Ltd’s holdings in Eli Lilly and Company were worth $66,029,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of LLY. BlackRock Inc. boosted its stake in shares of Eli Lilly and Company by 1.6% during the 2nd quarter. BlackRock Inc. now owns 67,540,400 shares of the company’s stock worth $81,009,981,000 after acquiring an additional 1,046,558 shares during the period. State Street Corp increased its holdings in shares of Eli Lilly and Company by 1.7% during the 2nd quarter. State Street Corp now owns 36,215,754 shares of the company’s stock worth $43,438,262,000 after acquiring an additional 605,752 shares during the last quarter. Bank of America Corp DE bought a new stake in Eli Lilly and Company in the 2nd quarter valued at $13,522,666,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in Eli Lilly and Company by 1.9% in the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 7,209,385 shares of the company’s stock valued at $8,647,153,000 after acquiring an additional 137,364 shares during the period. Finally, Jennison Associates LLC lifted its holdings in Eli Lilly and Company by 7.9% during the 2nd quarter. Jennison Associates LLC now owns 5,461,416 shares of the company’s stock valued at $6,550,587,000 after purchasing an additional 400,538 shares during the last quarter. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Stock Performance

Shares of NYSE LLY traded up $44.24 during trading hours on Wednesday, reaching $1,210.75. 1,364,541 shares of the stock were exchanged, compared to its average volume of 2,943,851. The firm has a market capitalization of $1.14 trillion, a price-to-earnings ratio of 40.65, a P/E/G ratio of 1.52 and a beta of 0.46. The stock’s fifty day simple moving average is $1,176.60 and its 200 day simple moving average is $1,102.08. The company has a debt-to-equity ratio of 1.41, a quick ratio of 1.00 and a current ratio of 1.35. Eli Lilly and Company has a 52 week low of $783.85 and a 52 week high of $1,292.65.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Wednesday, August 5th. The company reported $8.38 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.40 by $1.98. Eli Lilly and Company had a return on equity of 97.83% and a net margin of 33.53%. The business had revenue of $22.97 billion during the quarter, compared to the consensus estimate of $20.82 billion. During the same period in the previous year, the company posted $6.31 EPS. The firm’s quarterly revenue was up 47.7% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. Sell-side analysts predict that Eli Lilly and Company will post 34.79 EPS for the current year.

Insider Activity

In related news, EVP Anat Hakim sold 5,000 shares of the firm’s stock in a transaction dated Friday, August 7th. The shares were sold at an average price of $1,190.00, for a total transaction of $5,950,000.00. Following the transaction, the executive vice president directly owned 11,875 shares of the company’s stock, valued at approximately $14,131,250. This trade represents a 29.63% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Patrik Jonsson sold 6,500 shares of Eli Lilly and Company stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $1,175.10, for a total transaction of $7,638,150.00. Following the completion of the sale, the executive vice president owned 54,147 shares of the company’s stock, valued at $63,628,139.70. This trade represents a 10.72% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 13,500 shares of company stock valued at $15,958,170. 0.14% of the stock is owned by company insiders.

Eli Lilly and Company News Roundup

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Strong obesity and diabetes momentum: RBC expects Lilly could raise its full-year revenue outlook, supported by continued sales of Zepbound and other cardiometabolic products. Retatrutide is also viewed as a potentially larger future growth driver, with investor attention likely to intensify ahead of the company’s October 29 earnings report. RBC expects Lilly to raise revenue outlook
• Positive Sentiment: Favorable earnings expectations: Erste Group raised its FY2026 EPS estimate to $36.55 from $36.45 and its FY2027 estimate to $47.30. Analysts are also anticipating continued earnings growth in the upcoming third-quarter report. Eli Lilly earnings preview
• Positive Sentiment: Pipeline expansion: Lilly’s collaboration with Prelude Therapeutics will test an experimental breast-cancer drug in combination with established therapies, adding to its oncology pipeline. Broader industry cancer-drug spending is projected to exceed $400 billion by 2028, supporting long-term opportunity. Prelude clinical trial collaboration
• Neutral Sentiment: Valuation remains a key debate: Commentary highlights Lilly’s exceptional growth and potential undervaluation relative to its outlook, but the stock trades at a premium multiple, making execution and pipeline results important.
• Negative Sentiment: Clinical risks remain: A study of a combination involving Zepbound produced greater weight loss but substantially higher discontinuation rates, raising questions about tolerability and commercial adoption. Zepbound combination study

Wall Street Analyst Weigh In

A number of equities analysts have commented on LLY shares. Guggenheim lifted their price objective on shares of Eli Lilly and Company from $1,273.00 to $1,284.00 and gave the stock a “buy” rating in a research report on Friday, September 18th. UBS Group set a $1,376.00 price objective on shares of Eli Lilly and Company in a research report on Friday, August 7th. Wells Fargo & Company raised their target price on shares of Eli Lilly and Company from $1,280.00 to $1,330.00 and gave the stock an “overweight” rating in a research note on Thursday, August 6th. Bank of America lifted their target price on shares of Eli Lilly and Company from $1,251.00 to $1,334.00 and gave the stock a “buy” rating in a report on Friday, July 10th. Finally, JPMorgan Chase & Co. lifted their target price on shares of Eli Lilly and Company from $1,400.00 to $1,500.00 and gave the stock an “overweight” rating in a report on Monday, September 28th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Eli Lilly and Company has an average rating of “Moderate Buy” and an average target price of $1,313.43.

Eli Lilly and Company Profile

Eli Lilly and Company is a global pharmaceutical company headquartered in Indianapolis, Indiana. Founded in 1876 by Colonel Eli Lilly, the company researches, develops, manufactures and markets medicines for a range of conditions, including diabetes, obesity, cancer, immunological disorders, neurological diseases and pain.

Its products include Mounjaro and Zepbound, which contain tirzepatide and are used for type 2 diabetes and chronic weight management, respectively. Other key medicines include Trulicity for diabetes, Verzenio for certain breast cancers, Taltz for inflammatory and autoimmune conditions, Humalog insulin, and Kisunla for early symptomatic Alzheimer’s disease.